Received Mar 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 4 | 3044069 | IM / LA |
RESIDENT NOTED WITH CHANGE IN CONDITION EVENT ON 3/22/2025 1330- OXYGEN SATURATION @85% ON 2L OXYGEN VIA NASAL CANNULA, SHALLOW RESPIRATONS, SKIN COLOR NOTED TO BE PALE. VITAL SIGNS: BP 117/66, P 121 (IRREGULAR), RR 12, T 97.2, SPO2 85% VIA 2L NC, BS 191. NON-REBREATHER MASK PLACED ON RESIDENT WITH O2 SATURATION AT 100%. MD NOTIFIED WITH ORDER TO TRANSFER RESIDENT TO HOSPITAL FOR FURTHER EVALUATION, RESIDENT TRANSFERRED TO HOSPITAL WITH DX OF SEPSIS.
2/27/2025 ADMIT TO SNF W/ DX OF: RESPIRATORY FAILURE, UNSPECIFIED WITH HYPOXIA; SEPSIS, UNSPECIFIED ORGANISM; DYSPHAGIA, OROPHARYNGEAL PHASE; DIFFICULTY IN WALKING, NOT ELSEWHERE CLASSIFIED; OTHER SYMPTOMS AND SIGNS INVOLVING THE MUSCULOSKELETAL SYSTEM; TYPE 2 DIABETES MELLITUS WITH HYPERGLYCEMIA; INTERSTITIAL PULMONARY DISEASE, UNSPECIFIED; BRONCHIECTASIS, UNCOMPLICATED; PNEUMONIA, UNSPECIFIED ORGANISM
2/27/2025 ADMIT TO SNF W/ DX OF: RESPIRATORY FAILURE, UNSPECIFIED WITH HYPOXIA; SEPSIS, UNSPECIFIED ORGANISM; DYSPHAGIA, OROPHARYNGEAL PHASE; DIFFICULTY IN WALKING, NOT ELSEWHERE CLASSIFIED; OTHER SYMPTOMS AND SIGNS INVOLVING THE MUSCULOSKELETAL SYSTEM; TYPE 2 DIABETES MELLITUS WITH HYPERGLYCEMIA; INTERSTITIAL PULMONARY DISEASE, UNSPECIFIED; BRONCHIECTASIS, UNCOMPLICATED; PNEUMONIA, UNSPECIFIED ORGANISM
Diltiazem HCl Tablet 30 MG 1 TAB PO TID, Midodrine HCl Tablet 5 MG 1 TAB PO TID, Ferrous Sulfate Oral Tablet 325 (65 Fe) MG 1 TAB PO QD, Lactobacillus Oral Capsule 1 CAP PO QD, sulfaSALAzine Oral Tablet 500 MG 3 TAB PO BID, Juven Oral Pa
CODEINE, ETANERCEPT, NSAIDS, APPLES
N/A